



MTN 2018

State of the Network

Jared Baeten MD PhD
Co-PI, Microbicides Trials Network
Vice Chair, Department of Global Health
Professor, Departments of Global Health, Medicine, and Epidemiology
Director, UW/Fred Hutch Center for AIDS Research (CFAR)
Co-Director, International Clinical Research Center
University of Washington
MTN Annual Meeting, March 2018, Washington DC

Welcome to the MTN Annual Meeting

- Meet someone new
- Enjoy the plenary sessions
- Come to the reception tonight and see some great posters and chat with the MTN Friends and Family
- Think about how we can change HIV prevention for this world



HIV prevention 2018

- HIV testing, ART, VMMC continue to expand
- PrEP accessible in dozens of countries & now with evidence of population-level impact
- New PrEP options & vaccines in phase I-III

Celebrate

HIV prevention 2018

- New infections far outpace goals
- PrEP availability & use disproportionately low in cis & trans women, persons of color, youth
- Needs unmet for those who do not want PrEP



Filling the Gaps



Science that advances HIV prevention

- The MTN has brought a focused, efficient, and advancing scientific agenda
 - Robust virology, mucosal biology, pharmacology
 - Rigorous quantitative science
 - Integrated behavioral & social science
 - Operational and organizational oversight
 - Safety & regulatory expertise from phase I to III
 - Strong partnerships (academia, industry, community)

Let's preview the
next two days



Learning from our experiences

- Continuous actions to improve how we work, with lessons that translate to new protocols and to other work we do



Top 10 lessons from HOPE
Nyaradzo Mgodzi (today)

Listening to communities

- Stakeholder & end user work :
 - Want prevention products that are less “medicalized,” easier to use
 - Want empowering products, personal control

Hearing from a ring user
Ruth Nahurira (today)

TRIO & QUATRO: Key
insights from research with
end users of MPT and HIV
prevention products
Ariane van der Straten, Liz
Montgomery, Alexandra
Minnis (tomorrow)



Behaviorally congruent prevention

What people want




What people get



Proof of concept of on demand rectal microbicides
The double delights of douching
Craig Hendrix, Alex Carballo-Diequez (today)

Understanding the Life Cycle: pieces of the puzzle for dapivirine ring

Phase III, IIIb MTN-020, -025



Other safety MTN-012, -013, -036

Bleeding patters and
contraceptive
discontinuation

The path to the MPT
ring

Felix Muhlenga, Sharon
Achilles (tomorrow)

Prevention in pregnancy

- Pregnant women face high HIV risk
- The story of oral PrEP illustrates why prevention research in pregnancy must be a priority
 - with conflicting recommendations about whether to use and delayed access as a result



Ethical framework for evaluation of
HIV products in pregnant women

Anne Drapkin Lyerly (tomorrow)

Working across populations



Perspectives of youth and transgender people
on HIV prevention products
Al Liu, Kristina Rodriguez, Christopher
Balthazar, Shawn Demmons (today)

Thinking ahead to impact

- We develop prevention tools so that people will use them and the epidemic will change

PrEP in DREAMS

Estimating the incremental impact of HIV prevention interventions

Janet Saul & Ruanne Barnabas (tomorrow)






High uptake and reduced HIV-1 incidence in an open-label trial of the dapivirine ring

The MTN-025/HOPE Study Team
CROI 2018, Boston, USA


Open-label prevention

For PrEP, open-label extensions provided key information beyond what was learned in phase III trials, moving the field towards demonstration and scale-up:




Grant et al., NEJM 2010; Baeten et al., NEJM 2012; Grant et al., Lancet ID 2014; McCormack et al. Lancet 2016; Baeten et al., PLoS Med 2016

HIV incidence in HOPE



Comparison to other open-label data

- The HIV-1 incidence observed to date in MTN-025/HOPE compares favorably to that seen in prior open-label extension studies, for example iPrEx OLE:



HIV incidence in iPrEx OLE among the subset with high PrEP adherence was zero. Similar adherent subset analyses are not yet available for MTN-025/HOPE.

Science that advances HIV prevention

- Thus, we are potentially standing on the cusp of a new prevention product
 - One that is discrete, woman-controlled, well-tolerated, and desired
 - Supported by rigorously-done, collaborative, multinational work


The MTN journey with the dapivirine ring
Sharon Hillier (today)



People



Loss



We Move Forward



We Move Forward



Choice matters



Pill



Vaginal ring



Injectable



Vaginal/rectal
inserts



Vaginal films



Vaccine

- People's preferences and needs are not all the same
 - Analogy: for contraception, women regularly weigh side effects, efficacy, life burden, and “medicalization” when making choices
- People want options ... so they can make choices ... so they can be free of HIV

State of the Network



Welcome to the MTN Annual Meeting

